The indication is based on a phase 3 trial – Empower-Lung 1 – that showed Libtayo given as a monotherapy cut the risk of death by 43% compared to chemotherapy in advanced, PD-L1-high patients ...

Libtayo is also under review by the EMA as a ... approved as a monotherapy – and has the advantage that it can be given to patients regardless of their PD-L1 status. Sanofi and Regeneron are ...

The agreement was signed in a letter of intent March 3 to set the groundwork for whether government health programs in ...

Regeneron UK Limited today announced that the Scottish Medicines Consortium (SMC) has accepted Libtayo ® (cemiplimab) for use on the National Health Service as a second-line monotherapy treatment ...

The trial evaluates THIO's safety, tolerability, and efficacy in combination with PD-(L)1 inhibition. THIO sequenced with Libtayo extended overall survival in those with non–small cell lung cancer who ...

The supply agreement supports the evaluation of Immuneerings' lead product candidate, IMM-1-104, in combination with Regeneron's immunotherapy drug Libtayo in patients with advanced non-small cell ...

Regeneron UK Limited has announced that the Scottish Medicines Consortium (SMC) has accepted Libtayo (cemiplimab) for use on the National Health Service. This approval is for second-line monotherapy ...

Immuneering plans to evaluate IMM-1-104 in combination with Libtayo in patients with advanced non-small cell lung cancer in its ongoing Phase 2a trial – - Data presented at AACR 2023 supports ...